Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
This development is significant because it marks a concrete move toward making GelrinC available to patients in Europe. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process. It aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available.
For investors, the training initiative signals that Regentis is executing on its commercialization roadmap. Successful adoption could drive revenue growth and validate the company's platform technology. For patients, it offers hope for a minimally invasive solution to knee cartilage damage, potentially reducing the need for more complex surgeries. For the orthopedic industry, GelrinC represents a novel approach in regenerative medicine, setting the stage for broader use of synthetic hydrogels in tissue repair.
To view the full press release, visit https://ibn.fm/QOWWK.
